Through a simple blood draw, the new test offers robust analysis of over 200 genes and genomic immunotherapy biomarkers MSI and bTMB, guiding precise treatment strategies for primary and metastatic disease. The non-invasive nature of this test mitigates many of the challenges associated with invasive tumor biopsy procedures.

Prof. Philippos Patsalis, CEO Medicover Genetics Cyprus, stressed on the test’s clinical utility: “NeoThetis Pan-Cancer Plus panel is an important stride in improving personalized cancer care. Holistic understanding of cancer’s unique genetic characteristics is crucial for guiding precise therapeutic approaches. Our objective is to consistently connect the dots between genetic knowledge and patient care, and today, we've come a step closer to realizing that goal”.

The tested genes adhere to clinical practice guidelines established by professional bodies like NCCN, ESMO, and ASCO, and are linked to FDA/EMA-approved therapies and clinical trial eligibility criteria. The new panel incorporates Microsatellite Instability (MSI) analysis, a predictive biomarker for immunotherapy, and blood-based Tumor Mutational Burden (bTMB) analysis. As a tumor-agnostic biomarker, bTMB unveils prognostic insights and therapeutic avenues for patients across the spectrum of solid tumors, rare types included. Pan-Cancer Plus delivers over 1Mb of genomic coverage and targets more than 2000 genetic loci, ensuring accurate bTMB scoring and MSI assessment respectively. The comprehensive assessment of MSI and bTMB uncovers new opportunities for approved or suggested targeted therapies and immunotherapy-related clinical trials.

The development of NeoThetis Pan-Cancer Plus underscores Medicover Genetics' commitment to aiding patients on their cancer treatment journey and supporting healthcare professionals with the knowledge to make informed decisions, enhancing clinical management and patient care.